company background image

Adamis Pharmaceuticals NasdaqCM:ADMP Stock Report

Last Price


Market Cap







24 Mar, 2023


Company Financials

Adamis Pharmaceuticals Corporation

NasdaqCM:ADMP Stock Report

Mkt Cap: US$20.0m

ADMP Stock Overview

About the company

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injectable pre-filled single dose syringe products for use in the emergency treatment of acute allergic reactions comprising anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was founded in 2006 and is headquartered in San Diego, California.

Snowflake Analysis

ADMP fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health0/6

My Notes

Capture your thoughts, links and company narrative

Adamis Pharmaceuticals Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Adamis Pharmaceuticals
Historical stock prices
Current Share PriceUS$0.12
52 Week HighUS$0.62
52 Week LowUS$0.099
1 Month Change-57.15%
3 Month Change-23.72%
1 Year Change-80.17%
3 Year Change-67.49%
5 Year Change-96.60%
Change since IPO-98.98%

Recent News & Updates

Adamis Pharmaceuticals: Managing A Position In A Company Diagnosed With Chronic Failure

Sep 30

Recent updates

Adamis Pharmaceuticals: Managing A Position In A Company Diagnosed With Chronic Failure

Sep 30

Next meeting of data safety board to review Adamis Pharma's COVID treatment in Sept.

Jul 29

Adamis CEO urges stock split approval, slate of directors in letter to shareholders

Jul 21

Adamis Pharmaceuticals: Preparing For Another Round Of Success, Failure, Then Hope

Apr 13

Adamis Pharmaceuticals: Market Continues To Overlook TEMPOL's Potential To Be A Leading COVID-19 Therapeutic

Jan 20

Adamis Pharmaceuticals: It's Now Or Never

Dec 02

Adamis Pharmaceuticals: TEMPOL's Near-Term And Long-Term Upside Improves As Variants Sidestep Vaccines

Sep 03

Adamis Pharmaceuticals: Potential COVID Drug Could Reignite Shares

Jun 13

Adamis Pharma gains 9% after Tempol shows potential as an antiviral drug for COVID-19

Jun 07

Adamis pharmaceuticals gets deficiency letter from NASDAQ

May 28

Adamis Pharmaceuticals (ADMP) trades sharply lower after pricing public offering

Jan 29

Adamis Pharma plunges 43% on FDA rejection of Zimhi application for opioid overdose

Nov 16

Adamis Pharmaceuticals EPS misses by $0.01, misses on revenue

Nov 09

Shareholder Returns

ADMPUS PharmaceuticalsUS Market

Return vs Industry: ADMP underperformed the US Pharmaceuticals industry which returned -6.1% over the past year.

Return vs Market: ADMP underperformed the US Market which returned -14.8% over the past year.

Price Volatility

Is ADMP's price volatile compared to industry and market?
ADMP volatility
ADMP Average Weekly Movement15.6%
Pharmaceuticals Industry Average Movement10.8%
Market Average Movement6.5%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.0%

Stable Share Price: ADMP is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: ADMP's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.

Adamis Pharmaceuticals Corporation Fundamentals Summary

How do Adamis Pharmaceuticals's earnings and revenue compare to its market cap?
ADMP fundamental statistics
Market CapUS$19.98m
Earnings (TTM)-US$26.20m
Revenue (TTM)US$4.76m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ADMP income statement (TTM)
Cost of RevenueUS$6.19m
Gross Profit-US$1.43m
Other ExpensesUS$24.77m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date


Earnings per share (EPS)-0.16
Gross Margin-30.10%
Net Profit Margin-550.86%
Debt/Equity Ratio-47.0%

How did ADMP perform over the long term?

See historical performance and comparison